If you are interested in buying Eli Lilly (NYSE: LLY) today, it is most likely because of the success of the company's GLP-1 ...

Eli Lilly (LLY) closed at $916.31 in the latest trading session, marking a +1.47% move from the prior day. This change outpaced the S&P 500's 0.54% gain on the day. Elsewhere, the Dow saw an upswing ...

A catalyst for stock performance may be just ahead.

Eli Lilly (LLY) stock drops as HSBC downgrades the company warning that weight-loss drugmaker could be “priced to perfection.

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...

Back in December, 12 mg retatrutide was linked to an efficacy estimand weight loss of 28.7%—and a 75.8% reduction in pain scores—in a phase 3 trial of the triple agonist in patients with both obesity ...

Eli Lilly is rated SELL due to lofty valuation, despite extraordinary execution and recent market leadership in GLP-1 and obesity drugs. LLY's current $950B market cap implies sustained 25% annual ...

In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound Participants who ...

Eli Lilly and Co.’s career website this month listed 254 job openings in Indianapolis and another 90 in nearby Lebanon, accounting for more than three-quarters of the 445 open positions the ...

The Lilly Technology Center investment includes expanding existing capabilities and the establishment of new production lines.